肝癌免疫治疗潜在耐药机制分析  

Analysis of potential resistance mechanism of liver cancer immunotherapy

作　　者：陆彦岑 陈聪燕 陈旭晓 陈拥军[1] Lu Yancen;Chen Congyan;Chen Xuxiao;Chen Yongjun(Department of Hepatobiliary Surgery,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院肝胆外科,上海200025

出　　处：《中华肝胆外科杂志》2022年第6期465-469,共5页Chinese Journal of Hepatobiliary Surgery

基　　金：国家自然科学基金(81902961);上海市青年科技英才扬帆计划项目(19YF1407400)。

摘　　要：肝癌是临床常见的恶性肿瘤之一,其发病率逐年增加,大多数患者诊断时已处于中晚期阶段,往往预后较差。肝癌的发生发展与免疫系统的消除、平衡、逃逸三个阶段密切相关。近年来,免疫检查点抑制剂已经在临床研究中取得了广泛进展和应用,为改善晚期肝癌患者生存率带来了明显转机。但同时,药物治疗的耐药性随之而来。肿瘤细胞对药物反应性较差,是严重影响临床预后的一大问题。本文对肝癌免疫治疗中先天性耐药和获得性耐药的潜在发生机制作一综述。Liver cancer is one of the common malignant tumors in clinic,and the incidence rate has been increasing year by year.Most patients are diagnosed at the advanced stage,and the prognosis is poor.The occurrence and development of hepatocellular carcinoma is closely associated with immune elimination,balance and escape.In recent years,checkpoint inhibitors have been used in clinic and immune checkpoint inhibitors have made extensive progress and application in clinical research,which has brought a significant opportunity to improve the survival rate of patients with advanced liver cancer.However,HCC patients develop immunotherapy resistance afterwords.The poor drug response to tumor cells is a serious problem affecting the clinical prognosis.This review briefly summarizes the potential mechanism of innate resistance and acquired resistance in immunotherapy of liver cancer.

关 键 词：癌 肝细胞 抗药性 免疫疗法 免疫检查点抑制剂 

分 类 号：R735.7[医药卫生—肿瘤]